Loading
Life sciences · Journal article
British Journal of Haematology · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 paediatric, 14 adolescents and young adults, 14 adults) with R/R non‐Hodgkin lymphomas enrolled in Canadian precision oncology initiatives (Personalized Oncogenomics, Precision Oncology for Young People, Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood, SickKids' Cancer Sequencing). WGTA provided clinically potentially useful findings in 89% of patients including therapy selection, diagnostic clarification, prediction of resistance, minimal residual disease marker identification and discovery of germline cancer predisposition. Results altered management in 15% of patients. Barriers to implementation included clinical deterioration, availability of standard therapies reducing the need for sequence‐informed therapies and limited access to targeted agents. Transcriptome‐based clustering delineated five biologically distinct subgroups independent of age or histological subtype with convergent oncogenic pathways. Mutational signature analysis identified hypermutation patterns consistent with genomic damage associated with prior cytotoxic therapies. While our findings support the integration of WGTA into the care of patients with R/R lymphomas and identify opportunities for sequence‐guided treatment, drug access, systematic barriers and delayed timing of testing currently limit clinical uptake and the potential of precision oncology in lymphoid malignancies.